Modelling the Protective Efficacy of Alternative Delivery Schedules for Intermittent Preventive Treatment of Malaria in Infants and Children by Cairns, M et al.
Modelling the Protective Efficacy of Alternative Delivery
Schedules for Intermittent Preventive Treatment of
Malaria in Infants and Children
Matthew Cairns1*, Azra Ghani2, Lucy Okell2, Roly Gosling1, Ilona Carneiro1, Francis Anto3,
Victor Asoala3, Seth Owusu-Agyei4, Brian Greenwood1, Daniel Chandramohan1, Paul Milligan1
1 London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Imperial College, London, United Kingdom, 3Navrongo Health Research Centre,
Navrongo, Ghana, 4 Kintampo Health Research Centre, Kintampo, Ghana
Abstract
Background: Intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP) is recommended by
WHO where malaria incidence in infancy is high and SP resistance is low. The current delivery strategy is via routine
Expanded Program on Immunisation contacts during infancy (EPI-IPTi). However, improvements to this approach may be
possible where malaria transmission is seasonal, or where the malaria burden lies mainly outside infancy.
Methods and Findings: A mathematical model was developed to estimate the protective efficacy (PE) of IPT against clinical
malaria in children aged 2-24 months, using entomological and epidemiological data from an EPI-IPTi trial in Navrongo,
Ghana to parameterise the model. The protection achieved by seasonally-targeted IPT in infants (sIPTi), seasonal IPT in
children (sIPTc), and by case-management with long-acting artemisinin combination therapies (LA-ACTs) was predicted for
Navrongo and for sites with different transmission intensity and seasonality. In Navrongo, the predicted PE of sIPTi was 26%
by 24 months of age, compared to 16% with EPI-IPTi. sIPTc given to all children under 2 years would provide PE of 52% by
24 months of age. Seasonally-targeted IPT retained its advantages in a range of transmission patterns. Under certain
circumstances, LA-ACTs for case-management may provide similar protection to EPI-IPTi. However, EPI-IPTi or sIPT
combined with LA-ACTs would be substantially more protective than either strategy used alone.
Conclusion: Delivery of IPT to infants via the EPI is sub-optimal because individuals are not protected by IPT at the time of
highest malaria risk, and because older children are not protected. Alternative delivery strategies to the EPI are needed
where transmission varies seasonally or the malaria burden extends beyond infancy. Long-acting ACTs may also make
important reductions in malaria incidence. However, delivery systems must be developed to ensure that both forms of
chemoprevention reach the individuals who are most exposed to malaria.
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Introduction
Intermittent preventive treatment of malaria in infants (IPTi)
consists of a full therapeutic course of antimalarial drugs given at
the time of Expanded Program on Immunisation (EPI) vaccination
in infancy. EPI-linked IPTi using sulphadoxine-pyrimethamine
(SP) provides a protective efficacy (PE) of approximately 30%
against clinical episodes of malaria during infancy [1]. EPI-IPTi
has been extensively evaluated and has been shown to be safe,
well-tolerated, acceptable and highly cost-effective [1,2,3,4]; EPI-
IPTi is now recommended as policy by WHO in areas with a high
burden of malaria in infancy and a low prevalence of SP resistance
[5]. However, some uncertainty remains about whether the
currently recommended EPI-linked IPTi strategy could be
adapted to certain settings to improve efficacy, particularly where
malaria transmission is seasonal or where a large part of the
malaria burden occurs outside infancy. Therefore, it would be
helpful to know how alternative forms of chemoprevention would
compare to IPTi delivered through EPI.
One potential alternative to EPI-IPTi is seasonally-targeted
intermittent preventive treatment, where IPT is delivered at the
time of peak malaria transmission rather than at the time of age-
based EPI vaccination contacts. Seasonal IPT could be restricted
to infants alone, or extended to include children above one year of
age. A number of studies have shown that seasonal IPT in young
children is very effective in preventing malaria when given at the
time of peak transmission [6,7,8,9]. If the challenges of delivering
the intervention outside the structure of the EPI can be met, there
are potentially two major advantages of seasonally-targeted IPT.
Firstly, because the major benefit of IPT is probably short-term
chemoprophylaxis [10,11,12], delivering courses of IPT at the
time of greatest malaria risk will avert more cases of malaria.
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Secondly, a delivery system set up to deliver IPT outside the EPI
would be able to include young children in addition to infants, and
thus help to tackle the malaria burden outside infancy. Young
children may suffer more severe malaria than infants in certain
epidemiological settings [13,14], and the malaria burden in infants
may decrease further relative to that in children in the context of
falling transmission intensity and other control efforts [15,16,17].
Another possible means to prevent malaria through the use of
antimalarials would be to use long-acting drugs for the treatment
of malaria cases. Both malaria infection and clinical malaria are
overdispersed, meaning that some children suffer multiple malaria
episodes while others around them suffer no malaria. A clinical
malaria episode is thus a strong predictor of subsequent episodes
[18,19]. New long-acting artemisinin combination therapies (LA-
ACTs), which include a long-acting partner drug (e.g. piperaquine,
pyronaridine or mefloquine) may offer post-treatment prophylaxis
to the children who most need protection from malaria [20].
Reductions in overall malaria incidence have been seen when
ACTs with long-acting partner drugs were introducted in
Zanzibar and in South East Asia [21,22]. Where the malaria
burden is seasonal, use of LA-ACTs for malaria case management
may also protect children from further episodes of malaria at the
time of year when they are most at risk. Where LA-ACTs are
widely available for case management, this could therefore prevent
as well as treat malaria.
In this study, a mathematical model was developed to
investigate the protective efficacy of IPTi delivered at EPI
vaccination contacts in infancy, and three alternatives, namely
seasonal IPT in infants (sIPTi), seasonal IPT in children (sIPTc)
and the use of long-acting ACTs for case-management of malaria
(LA-ACTs). This was undertaken first for a specific site in Ghana
for which detailed contemporaneous data on malaria incidence in
children ,24 months of age, entomological inoculation rate (EIR),
and SP-IPTi efficacy were available. The site represents an area
where malaria transmission is highly seasonal, although there is
some transmission throughout the year. Under such conditions,
the advantages of seasonal targeting are less obvious than in areas
with a very short transmission season each year, such as many
areas of the Sahel [23]. The model was then extended to consider
the impact of these different strategies in sites with a range of
seasonality and transmission intensity patterns.
Methods
Data
This study used data from the Navrongo IPTi study, which took
place in Kassena-Nankana District (KND), Ghana between 2000
and 2004. The IPTi trial is described in detail elsewhere [24]. In
brief, four courses of SP or placebo were given to infants at 3, 4
and 9 months of age at the time of an EPI contact and at 12
months during a growth-monitoring visit. Passive case detection of
malaria continued until children reached two years of age. This
analysis therefore focuses on children less than 24 months of age.
Incidence rates of malaria by calendar month in the intervention
and control groups were calculated from the IPTi trial data.
Entomological inoculation rate (EIR) in each calendar month was
provided by an entomological study which took place in KND
during the period of the trial (Anto et al. [25], unpublished).
Model development
A set of deterministic compartmental models was developed.
These are specified as sets of differential equations which describe
changes over calendar time in the number of individuals in each
compartment. The model equations are described in detail in
Supporting Information S1. The infection status of the human
population (,24 months of age) in calendar time is described by a
compartmental model. For simplicity, there is no analogous
mosquito component: this is replaced with a function representing
the entomological inoculation rate, with monthly values estimated
from the recorded entomological data.
In the model, children can be in one of the following states:
uninfected (U), previously uninfected incubating infection (E1),
previously asymptomatic/untreated incubating superinfection
(E2), asymptomatic or untreated parasitaemia (A), symptomatic
and treated (S) or protected by IPT (I) (figure 1). Children enter
the model at 2 months of age, the age of recruitment in the trial,
and are assumed to be uninfected at this time. Uninfected
children become infected at a rate which depends on the
entomological inoculation rate and the probability that an
infective bite results in infection. Infected individuals transfer to
E1, which represents the incubating state. A proportion of newly
infected children become symptomatic at the end of the
incubation period and move into compartment S. The remainder
develop asymptomatic parasitaemia and transfer to A. For
simplicity it is assumed that once asymptomatic, children do
not subsequently develop symptoms unless they are reinfected.
Children with asymptomatic parasitaemia recover via three
additional compartments before returning to the susceptible
state. The use of four compartments for the infected state makes
the distribution of time spent infected more realistic than if a
single compartment with a constant rate of recovery was used: the
total duration of protection then follows a gamma distribution
rather than an exponential distribution [26]; this also allows a
simple means of including the effect of superinfection [27].
Children who are superinfected enter an incubating compart-
ment, E2, after which a proportion develop symptoms and are
treated (moving from E2 into S), or remain asymptomatic and
return to A1. In the simplest case, the probability of developing
symptoms was assumed to be the same for both newly infected
children and children with superinfections; this assumption was
relaxed in later versions of the model. Acquisition of clinical
immunity with increasing age is accounted for by allowing the
proportion of infected children that develop clinical symptoms to
vary between age groups. To incorporate effects of maternally-
derived immunity, the probability that an infectious bite results in
infection is assumed to be lower early in infancy than later (see
Supporting Information S1 for details).
Because the intention was to validate the model with trial data,
we assumed that all children who had symptomatic infections and
who reported to trial staff were treated. In the model, treated
children recover faster than untreated or asymptomatic children
and receive a period of post-treatment prophylaxis (PTP) when
they cannot be reinfected. This is modelled by delaying the return
of treated children to the uninfected (and susceptible) compart-
ment, U, via a series of sub-compartments as described above [26].
Chloroquine (CQ) was the antimalarial most commonly used for
first line treatment during the Navrongo trial. Post-treatment
prophylaxis against erythrocytic stages may last for as little as two
weeks where CQ resistance is high [20], as was the case in
Navrongo at the time of the trial [28].
This model structure describes the transmission dynamics in the
control group of the Navrongo trial. For the intervention group,
an identical set of equations is used but with the addition of
compartments representing intermittent preventive treatment.
The model was stratified into two separate age groups (infants
,12 months of age, and children 12–23 months of age), allowing
the impact of IPT given to specific age groups to be explored. The
model was further stratified to reflect heterogeneity in malaria
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exposure, assuming that 20% of individuals receive 80% of all
infections [13,29].
The proportion of individuals successfully protected by IPT
depends on the coverage of IPT and the proportion of IPT courses
that are efficacious. It was assumed that a course of IPT would be
ineffective in a certain proportion of children who received IPT,
either due to drug resistance of P. falciparum, receipt of an
insufficient dose of SP, vomiting of treatment, or other similar
reasons. It is assumed that an efficacious course of IPT will clear
parasitaemia. In addition to its curative effect, IPT is considered to
provide prophylactic protection against new infections. Individuals
protected by IPT move into the IPT component of the model and
remain in this state for a variable period before returning to U. As
for the symptomatic treatment component, the IPT component is
modelled with multiple compartments such that the duration spent
protected follows a gamma distribution. Implementation of IPT is
modelled in one of two ways, reflecting two different delivery
strategies: 1) EPI-linked IPT delivered to infants at specific age-
based vaccination contacts (EPI-IPTi) and 2) IPT given outside the
EPI programme to all infants, regardless of their exact age, as
simultaneous mass treatments during the season of highest malaria
transmission (sIPT). With IPT given via the EPI, the cohort of
infants receives IPT throughout the year as members reach the
appropriate age to attend vaccination clinics (for Navrongo this
was 3, 4 and 9 months with an additional growth monitoring visit
at 12 months of age). With seasonal-IPT, all infants receive IPT at
specific times of year according to the peak in transmission
(figure 2).
Parameter estimation and model validation
The model was developed and parameterised to reflect the
situation of the Navrongo trial, and parameter values were
estimated from data from the trial and trial area before
consideration of other settings. Enrolment rate over calendar time
is based on trial data. The magnitude and duration of protection
against malaria from IPTi were estimated as previously described
[10]. The EIR function represents the fluctuations in the force of
infection over time, which were estimated using the data collected
in KND during the trial period by Anto et al. ([25], unpublished
data). Other parameter estimates were obtained from the
literature. Key parameters and their values are given in table 1;
a full list is given in Supporting Information S1. Cumulative
malaria incidence in each month in the model was fitted
simultaneously to monthly incidence data from four groups in
the trial (infants and one year old children in both the SP and
placebo groups). Fitting was carried out using the optimize
algorithm in Berkeley Madonna (version 8.3.11, University of
California) by varying h, the proportion of infections that are
symptomatic and treated, in order to maximise the binomial log-
likelihood function. When children in KND were followed actively
after radical cure, around 30–35% developed symptoms upon first
infection [30]. The proportion of symptomatic infections detected
passively is likely to be somewhat lower, because not all children
with malaria will present for treatment. Values of h estimated by
fitting the model were 23.7% for infants and 20.4% for one year
old children, both of which are biologically plausible. A sensitivity
analysis was carried out by varying the parameters of the model
within the range indicated in the Supporting Information S1.
Protective efficacy of EPI-IPTi and seasonal IPT in infancy
For all analyses, PE was calculated by comparing the
cumulative incidence by 24 months of age predicted by the model
in the intervention and control groups (i.e. among those children
given EPI-IPTi in addition to normal-case management, and those
given only case-management). Firstly, IPTi delivered through the
EPI as in the Navrongo trial was compared to a seasonal IPT
strategy in which the same number of courses of treatment (four)
was delivered to all infants, regardless of their exact age, on a
Figure 1. Overview of IPT model structure. The main states and transitions in the model are shown. IPT is indicated by dashed lines. There are
multiple analogous components in the model: the diagram represents one combination of age, intervention and exposure group.
doi:10.1371/journal.pone.0018947.g001
Modelling IPT Strategies in Infants and Children
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18947
monthly basis during the peak transmission period. Secondly, the
PE of different seasonal IPT strategies was investigated by varying
the number of IPT courses per year, the timing of IPT courses,
and the coverage of each IPT course. Thirdly, the effect of using a
longer-acting drug for sIPT or EPI-IPTi on the relative benefit of
seasonal targeting was investigated.
Protective efficacy of seasonal IPT in children
In later versions of the model, seasonal IPT was extended to
include children aged 12–23 months in addition to infants.
Although previous trials of IPT in children have usually included
children under 5 or 10 years of age, because the model is fitted to
the Navrongo trial cohort we simulate only the impact of including
one additional year of IPT and present protective efficacy at 24
months of age.
Long-acting ACTs for case-management of malaria
Finally, the effect of a long-acting drug regimen for case
management was investigated by varying the duration of
protection obtained after treatment for symptomatic malaria.
This was done both in the absence of IPT strategies, and alongside
EPI-IPTi, sIPTi and sIPTc.
Extension of the model to other sites
A previous study defined ‘marked seasonality’ as the occurrence
of more than 75% of the annual malaria incidence in six months of
the year [31]. Using similar logic, seasonality can be considered to
vary from 50% of annual incidence occurring within a 6 month
period (i.e. stable transmission all year) to 100% (highly seasonal).
Simple periodic functions were used to simulate varying degrees of
seasonal transmission ranging from 50% to 100% of transmission
within 6 months (at 10% intervals). We investigated the protective
efficacy of EPI-IPTi, sIPTi and sIPTc under these different
seasonality patterns, using two different transmission intensities:
high (EIR= 365, i.e. one infectious bite per individual per night, a
similar intensity to Navrongo) and low-moderate (EIR = 10, the
lower transmission intensity threshold recommended for imple-
mentation of IPTi).
Results
Malaria incidence by calendar month in Navrongo is shown in
figure 3. Incidence peaks between July and October and tails off
gradually into the dry season, corresponding closely with the
changes in EIR (figure 2).
Model validation and sensitivity analysis
Cumulative incidence of clinical malaria observed during the
Navrongo trial, and the corresponding values predicted by the
model are shown in figure 4. The model predictions agreed well
with the observed patterns. In particular, predicted cumulative
incidences in infancy were very close to the observed values. The
model slightly overestimated cumulative incidence in one year
old children, predicting around 100 more cases than actually
occurred, but this was similar in both the intervention and
control groups. The fitted model predicted protective efficacy for
EPI-linked IPT of 25.3% at 15 months of age and 15.6% by 24
months of age, very similar values to those obtained in the
clinical trial (24.9% at 15 months and 16.3% at 24 months of
age [24]). The sensitivity analysis (Supporting Information S1)
indicated that varying the parameter values did affect the point
estimates of protective efficacy, but in all cases the relative
magnitude of the differences between seasonal IPT and EPI-IPTi
remained similar.
Figure 2. Illustration of EPI-IPT and seasonal IPT in infants. The number of children given IPT with two different strategies: 1) four courses of
EPI- IPTi given at 3, 4, 9 & 12 months of age and 2) four courses of monthly seasonal IPT given to all infants regardless of their exact age. The EIR
function from the model fitted to EIR data from Navrongo is also shown. Fitting of the EIR function is described in detail in Supporting Information S1.
doi:10.1371/journal.pone.0018947.g002
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Protective efficacy of EPI-IPT and seasonal IPT in infancy
The model prediction of the efficacy of four courses of seasonal
IPT given to infants during the peak transmission season was 26.1%
at 24 months of age (table 2). Four courses of monthly seasonal IPT
given to infants with coverage of 53%would be equally protective as
four courses of EPI-IPTi with coverage of 92% (as in the clinical
trial). Assuming the same level of coverage, two seasonally-targeted
IPT courses in infancy alone would give similar protection to four
courses of IPTi given through the EPI (PE 14.9% and 15.6%
respectively). High efficacy would be achievable with multiple
courses of sIPT: with six courses of sIPT given monthly to infants,
protective efficacy would be 33.1% at 24 months of age.
The use of longer-acting drugs for IPT would increase protective
efficacy and reduce the advantages of seasonal targeting. However,
within the constraints of drugs that are currently available, targeting
IPT at the peak in transmission remains necessary to maximise
efficacy in seasonal settings. With a hypothetical IPT drug that
provided a mean of 90 days prophylaxis, longer than any currently
available antimalarial, four courses of EPI-IPTi would provide
protective efficacy by 24 months of age of 36.1%; this would be
42.3% with four courses of monthly seasonal IPT in infants.
Protective efficacy of seasonal IPT in children
The predicted PE of four monthly courses of sIPT given at the
peak in transmission during both the first and second years of life
was 51.7% between 2–24 months of age.
Long-acting ACTs for case-management of malaria
Use of a long-acting drug regimen for case management would
be expected to reduce the number of malaria cases in both the SP
and placebo groups. The PE of IPT would also decrease with
increasing post-treatment prophylaxis after curative treatment,
because more children would already be protected by their most
recent curative treatment at the time they receive IPT (table 2). In
model simulations, case management alone using a drug regimen
which provides a mean of 45 days of post-treatment prophylaxis
(PTP), prevented a similar number of malaria cases to a strategy of
EPI-linked IPTi with SP in conjunction with a shorter-acting
regimen for case management which provided 14 days PTP.
However, IPT of either type (EPI-IPTi or seasonal IPT) in
addition to a long-acting drug regimen for case management is
more efficacious than either strategy alone. Seasonal IPT in the
presence of long-acting regimens for case management retains its
relative advantage over EPI-IPTi, though the absolute benefits
would become smaller.
Extension of the model to other sites
Seasonal targeting of IPT given only to infants does not
improve efficacy in sites with completely uniform transmission
over the whole year, as would be expected (table 3). In sites with
a short transmission season of three months, the efficacy of
seasonal IPT given each year for two years was predicted to be
over 80% at 2 years of age, a finding that agrees with existing
Table 1. Descriptions and values of key model parameters.
Parameter description (units) Values from literature/data and source Best estimate (range)
Entomological inoculation rate Function fitted to entomological data (for Navrongo) or sinusoidal
function (other settings)
-
Probability an infective bite results in infection in a child 0.006 (High EIR), 0.07 (Low EIR) [41] 0.02 (0.005, 0.1)
0.026–0.073 (EIR = 1 per day) [42]
0.03–0.13 [43]
0.1 [44]
0.2
Rate individuals are infected Varies with time: determined by EIR and probability infective bite
results in infection
-
Mean duration of incubation period (days) 12 (9–14) [45] 10 (7, 14)
9 [46]
Mean duration of asymptomatic infection if untreated (days) 23 (highly endemic) [47] 100 (50, 200)
73 (,18 months of age)
160 (18–23 months) [48]
210 (176–256) [49]
210 (183–236) [50]
Proportion of new infections that are symptomatic 0.31 (KND, dry season),
0.34 (KND, wet season) [30]
0.44 (Kenya) [51]
% infections symptomatic and treated in infants Parameter fitted by the model 23.7% (5, 35)
% infections symptomatic and treated in 1 year olds Parameter fitted by the model 20.4% (5, 35)
Mean duration of prophylaxis after treatment for malaria (days) CQ during Navrongo trial
14-day ACPR 47% [28]
14 days PTP after CQ treatment [20]
14 (7, 21)
IPT Coverage 0.92 Navrongo data 0.92 (0.5, 0.95)
IPT Efficacy 14 day ACPR in KND: 0.78 [28]. Best estimate from model fitting. 0.9 (0.5–0.95)
Mean duration of prophylaxis after IPT (days) Protection for 28–42 days (SP) [10]
Up to 60 days [52]
Gamma distribution fitted to data.
30 (20–35)
doi:10.1371/journal.pone.0018947.t001
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trials of seasonal IPT in children (Supporting Information S1).
However, the conditions under which seasonal IPT may have
advantages over EPI-IPTi are not restricted to scenarios with
marked seasonality (table 3). An ability to target children outside
infancy would be an important advantage of alternative delivery
mechanisms, even in situations where malaria transmission is not
seasonal. The advantages observed were consistent in high and
low-moderate transmission settings.
Figure 3. Incidence of clinical malaria in the Navrongo IPTi trial. Incidence of clinical malaria between January 2001 and December 2003 is
shown for infants and children 12–23 months of age in the placebo group of the IPTi trial. Error bars indicate 95% confidence interval. Children were
enrolled between September 2000– June 2002. Completion of 24 months follow-up ended in June 2004.
doi:10.1371/journal.pone.0018947.g003
Figure 4. Cumulative malaria incidence predicted by the fitted model. Cumulative malaria incidence over the period of the Navrongo IPTi
trial. Points indicate incidence data from the trial; the dotted and solid lines indicate the fitted model predictions the for placebo and EPI-IPTi (IPTi)
groups respectively.
doi:10.1371/journal.pone.0018947.g004
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Discussion
Malaria chemoprevention by intermittent administration of
courses of antimalarials such as SP can provide personal
protection against sensitive parasites for about one month. The
impact of a particular strategy on the malaria burden will depend
on the age distribution and seasonal pattern of malaria in a
particular situation, the number and timing of treatment courses,
the age groups targeted, and the coverage achieved. Our
mathematical model helps to explain the likely impact of different
chemoprevention strategies in a range of epidemiological settings.
In Navrongo, an area with extended seasonal transmission, four
monthly courses of sIPT given only to infants would provide a
protective efficacy of 26.1% at 24 months of age. Seasonal IPT
would provide similar efficacy to EPI-IPTi even if the coverage
achieved by the alternative delivery system was markedly lower.
When possible differences in coverage among highly exposed
individuals were considered, seasonal IPT was predicted to be
more protective in all but the most extreme scenarios (Supporting
Information S1). Bojang et al. [32] compared EPI-based and
community-based delivery for IPT in children; both achieved
equitable coverage with respect to socioeconomic status deter-
mined from household assets. Furthermore, our model predicts
that seasonally-targeted IPT may be able to provide similar
protective efficacy to EPI-IPTi with fewer courses of drugs.
Longer-acting drugs for IPT would be expected to improve the
efficacy of both EPI-IPTi and seasonal IPT. However, with
sensible constraints on the duration of protection, benefits would
remain from seasonal IPT rather than EPI-IPTi.
The model simulations predicted that the use of a long-acting
regimen for malaria case management would lower overall
malaria incidence by providing post-treatment prophylaxis to
children who are treated for malaria. Reductions in transmission
as a result of ACT use have been predicted by previous modelling
studies [27] and have been observed in practice [21,22]. Our
model assumes that only individuals who actually have malaria
(and not those who receive treatment for fevers due to other
causes) would receive post-treatment prophylaxis, which follows
the current recommendation to treat only parasitologically
confirmed malaria with ACTs. The impact of post-treatment
prophylaxis from case management in situations where long-acting
antimalarials are used presumptively may be greater, and the
additional benefit of deliberate chemoprevention (whether EPI-
IPTi or seasonal IPT) correspondingly lower.
However, an important caveat is that the impact of long-acting
drugs predicted by this model is based on the assumption that in a
clinical trial, appropriate case management would be given to a
high proportion of symptomatic malaria cases. In reality, a smaller
proportion of the overall burden malaria cases are likely to be
treated and the impact of long-acting drugs on protecting
individuals who actually have malaria will be smaller. For this
reason, our findings do not support the use of long-acting
treatment drugs as an alternative to either IPT strategy, but
rather as a complementary approach.
Our results indicate that the use of a long-acting regimen for
case management of malaria in conjunction with either form of
IPT would be more effective than either form of IPT or long-
acting ACTs as a lone strategy. This is biologically plausible given
Table 2. Effect of long-acting drug for case management on IPT efficacy.
PTP from drug used
for case-management*
(days)
Predicted cases
by 24 months Cases averted by
Total cases
averted
Percent
averted
by IPT
PE of IPT
at 24 m (%)
Relative PE
of sIPT$ vs
EPI-IPTi
Placebo SP Treatment‘ IPT£
EPI-IPTi 14 2145 1810 - 335 335 - 15.6 -
30 1944 1659 201 286 487 59 14.7 -
45 1809 1560 336 248 584 42 13.7 -
60 1705 1488 440 217 657 33 12.8 -
90 1559 1389 586 169 755 22 10.9 -
sIPT
in
infancy
14 2145 1584 - 561 561 - 26.1 1.7
30 1944 1466 201 478 679 70 24.6 1.7
45 1809 1389 336 420 756 56 23.2 1.7
60 1705 1331 440 374 814 46 21.9 1.7
90 1559 1251 586 308 894 34 19.8 1.8
sIPT in
children,24
months
14 2145 1036 - 1109 1109 - 51.7 3.3
30 1944 987 201 957 1158 83 49.2 3.3
45 1809 959 336 850 1186 72 47.0 3.4
60 1705 939 440 766 1206 64 44.9 3.5
90 1559 912 586 647 1233 52 41.5 3.8
* Mean duration of post-treatment prophylaxis after treatment for a symptomatic malaria episode, 14 days is the value assumed for CQ in Navrongo. For this analysis,
duration of post-treatment prophylaxis after IPT was fixed at 30 days.
‘ cases averted relative to a drug for case management with mean duration of PTP of 14 days.
£Number of cases averted by IPT (difference between cases in placebo group and SP group) with treatment drug of same duration.
$Relative protective efficacy of seasonal IPT versus EPI-IPTi with same duration of PTP after treatment for symptomatic malaria.
doi:10.1371/journal.pone.0018947.t002
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that case-management cannot prevent first episodes, but will
prevent additional episodes in highly exposed children, whereas
EPI-IPTi or sIPT can also prevent initial malaria episodes. Thus,
while providing long-acting drugs for treatment may be of some
value where no infrastructure exists to deliver IPT or other forms
of chemoprevention (either via the EPI or via other approaches),
this will not be as effective as use of long-acting drugs in addition
to deliberate chemoprevention by IPT. These findings are in
agreement with two studies in Ghana of seasonal IPT in addition
to home management of malaria with long-acting drugs [33] and
[34].
For most of the range of transmission patterns considered, IPT
courses given in infancy during the part of the year when
transmission peaks predicted higher efficacy than a four-course
EPI-linked IPT program, with a clear advantage in settings with
‘marked seasonality’ [31]. Given that EPI-IPTi is likely to
incorporate only three courses (given with DTP2, DPT3 and
measles) rather than the four courses included in this simulation,
and that seasonal IPT could potentially be optimised further (by
including more courses or adjusting the interval to suit the
particular drug used), these differences may be conservative.
Under uniform perennial transmission, the model predicts that
four courses of monthly seasonal-IPT in infancy would give slightly
less protection to infants than four courses of conventional EPI-
IPTi. However, this could be improved by spacing courses further
apart so that the maximum benefit is obtained from each course
(i.e. there is no overlap between periods of prophylaxis).
The results presented show that if a delivery system can be
developed outside the EPI for the delivery of seasonal IPT,
inclusion of young children in addition to infants would offer
important advantages. However, the challenges of developing an
alternative delivery system could be substantial. In addition to
requiring an alternative delivery mechanism, seasonal IPT given
for the first few years of life will require more courses of IPT than
EPI-IPTi (even if fewer courses are given per year), may achieve
lower coverage, and would be more costly. However, the gains
achieved by protecting older children who are at high risk of
severe malaria could be substantial.
We have limited our analyses to children less than two years old
and focused on protective efficacy at 24 months of age for two
reasons. Firstly, in order to model the Navrongo cohort in detail,
which was only followed-up until two years of age, and secondly,
to show the impact on extending for a single year beyond infancy.
Our model suggests that with four monthly courses of seasonal
IPT in each of the first two years of life, PE would have been
51.7% at 24 months of age. Equivalent protective efficacy to IPT
strategies targeting only infants may be achievable with lower
coverage or fewer courses. Where seasonal IPT has been evaluated
in practice, older children up to 5 or 10 years have been included.
The potential advantages of a delivery system capable of
administering IPT to older children would be even greater than
that shown here. Furthermore, the protective efficacy of seasonal
IPT covering a broader age range would be less affected by any
future shift in the age-specific disease burden as a consequence of
reduced malaria transmission than would EPI-linked IPT given
only to infants. In the context of reducing malaria transmission in
some parts of Africa [16], and widespread efforts to reduce
transmission in other areas, this may be a very important
advantage.
Despite the potential advantages of seasonal IPT in children,
there are several important factors in addition to protective
efficacy that must be considered when comparing seasonal IPT to
EPI-IPTi. Several factors were not taken into account in the
models, which focused on the direct protection against clinical
malaria. This analysis does not consider potential differences in the
cost of the alternative delivery strategies, which will weigh against
the gains in protection since EPI-IPTi has been shown to be highly
cost-effective. However, seasonal IPT using community based
health-workers has been piloted in several countries, and can
achieve high coverage at moderate cost [35,36]. Other concerns
Table 3. Protective efficacy of EPI-IPTi and seasonal IPT by epidemiological setting.
Protective efficacy by 24 months of age (%) Relative protective efficacy
Transmission in peak 6
months of the year (%) EPI-IPTi sIPTi sIPTc
sIPTi vs.
EPI- IPTi
sIPTc vs.
EPI-IPTi
High EIR (365)
50 15.8 14.5 28.9 0.9 1.8
60 15.7 16.6 33.0 1.1 2.1
70 15.6 18.9 37.6 1.2 2.4
80 15.4 21.8 43.3 1.4 2.8
90 15.1 25.5 50.7 1.7 3.4
100 14.9 31.8 63.3 2.1 4.3
Low-moderate EIR (10)
50 17.2 15.1 30.8 0.9 1.8
60 17.1 18.3 37.7 1.1 2.2
70 16.9 21.5 44.8 1.3 2.7
80 16.8 24.7 51.9 1.5 3.1
90 16.6 28.0 59.5 1.7 3.6
100 16.5 32.6 71.7 2.0 4.4
Protective efficacy of EPI-linked intermittent preventive treatment in infants (EPI-IPTi) and seasonal IPT under different seasonality and transmission intensity. EPI-IPTi
delivered at 3, 4, 9 and 12 months of age. Seasonal IPT consists of four monthly courses of seasonal IPT targeted at the peak in transmission given to infants alone (sIPTi)
or to all children ,24 months of age (sIPTc).EIR: entomological inoculation rate.
doi:10.1371/journal.pone.0018947.t003
Modelling IPT Strategies in Infants and Children
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18947
include the potential impact on drug resistance, possible rebound
effects, and the safety of multiple courses. However, the
demonstration that equivalent efficacy can be achieved with fewer
targeted courses appears to be an advantage of seasonally-targeted
delivery in settings in which SP resistance is limited.
Rebound effects were not modelled since the mechanisms by
which such effects might be seen are only speculative at present.
Nevertheless, this issue requires further study since a temporary
increase in incidence of clinical malaria was observed in children
given long-term chemoprophylaxis [37]. The effect of SP
resistance on IPTi efficacy has been addressed in other studies
[38,39], and the effect of IPT on resistance has also been
addressed by modelling studies [40]. These studies found an
overall trend of decreasing efficacy with increasing SP resistance,
but the exact relationship between prevalence of key resistance
markers and IPT efficacy is not well characterised. We considered
whether the findings of this study would be robust in settings with
different SP resistance patterns by varying curative efficacy and
the duration of post-treatment prophylaxis after IPT (the two key
aspects that would be affected by SP resistance). While increasing
SP resistance does lower the efficacy of each dose of IPT and
shorten the period of prophylaxis, leading to lower estimates of
protective efficacy, the relative advantage of seasonal IPT over
EPI-IPT would remain at a given level of resistance (Supporting
Information S1).
Our model was initially parameterised using data collected in
Navrongo, Ghana. Some of the values of parameters are likely to
differ in other settings, including the proportion of infections that
are symptomatic, the recovery rate, and the proportion of
infectious bites that lead to a successful infection [41,42]. The
efficacy of IPT strategies and of treatment drugs will also vary in
different settings. Despite these limitations, the broad findings of
this analysis did not depend strongly on specific values of any
parameter. Furthermore, our predictions are consistent with
results of trials that have investigated different IPT dosing
schedules in seasonal transmission settings [6,7,8].
In summary, while IPTi delivered through the EPI is likely to be
a valuable malaria control tool in certain situations, particularly
those with high transmission, seasonal IPT targeted at the peak
transmission period may provide greater protection in other
epidemiological settings. Long-acting regimens for case manage-
ment may complement the protection provided by IPT, but for
case-management to have an impact as large as that indicated
here, it will be necessary to ensure that these antimalarials reach
the children who are most exposed to malaria, typically the
individuals who also have poorer access to treatment. Extending
seasonal IPT to include young children as well as infants has
important additional advantages, and may become increasingly
relevant in the future if the reductions in malaria transmission seen
in parts of Africa can be achieved more widely and can be
sustained. Developing effective delivery mechanisms for these
alternative strategies is crucial to ensure the potential advantages
presented here can be achieved in practice.
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